Want to see HK:6628 full AI Analyst Report?
Top Page
Transcenta Holding Limited
(6628)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.71
â–¼(-68.49% Downside)
Action:Reiterated
Date:10/31/26
The score is primarily held down by weak financial performance (shrinking revenue, persistent losses, negative gross profit in 2025, and ongoing cash burn). Technicals add further pressure with a clear downtrend versus key moving averages and negative MACD. Valuation is only slightly supportive because a negative P/E indicates losses and there is no dividend yield provided.
Positive Factors
Integrated Biopharma Capabilities
The integrated value-chain model gives Transcenta capabilities spanning discovery through commercialization, supporting control across development stages. These capabilities can serve both its own pipeline and external development or manufacturing work, providing a durable platform for future product and service opportunities.
Negative Factors
Revenue Contraction
Material revenue contraction indicates weaker commercial scale and reduces the base from which Transcenta can fund research, development, and operations. If the decline persists, the company may have less ability to absorb fixed costs, support its pipeline, and achieve operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated Biopharma Capabilities
The integrated value-chain model gives Transcenta capabilities spanning discovery through commercialization, supporting control across development stages. These capabilities can serve both its own pipeline and external development or manufacturing work, providing a durable platform for future product and service opportunities.
Read all positive factors
Transcenta Holding Limited (6628) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$327.59M
Dividend YieldN/A
Average Volume (3M)910.77K
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue Growth215.14%
EPS Growth40.49%
CountryHK
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding455,838,560
10 Day Avg. Volume687,100
30 Day Avg. Volume910,768
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.28
Price to Sales (P/S)108.90
P/FCF Ratio-5.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)HK$15.24M
Transcenta Holding Limited Business Overview & Revenue Model
Company Description
Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The c...
Transcenta Holding Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.32M | 7.24M | 11.26M | 53.85M | 101.89M | 50.24M |
| Gross Profit | 18.34M | -40.75M | 4.00M | 14.40M | 19.89M | 9.37M |
| EBITDA | -100.16M | -146.86M | -228.09M | -393.01M | -334.09M | -1.65B |
| Net Income | -161.29M | -198.45M | -290.29M | -462.57M | -406.75M | -1.72B |
Balance Sheet | ||||||
| Total Assets | 891.60M | 925.23M | 1.20B | 1.69B | 2.13B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 3.50M | 14.15M | 169.42M | 546.03M | 895.45M | 1.22B |
| Total Debt | 137.79M | 126.26M | 250.61M | 409.63M | 411.46M | 364.71M |
| Total Liabilities | 338.51M | 306.87M | 448.64M | 665.67M | 660.64M | 579.39M |
| Stockholders Equity | 553.09M | 618.36M | 751.64M | 1.03B | 1.47B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | -72.63M | -142.97M | -216.15M | -373.80M | -318.03M | -457.84M |
| Operating Cash Flow | -69.42M | -135.67M | -213.83M | -358.04M | -295.81M | -384.50M |
| Investing Cash Flow | 58.34M | 55.48M | 14.28M | 57.47M | -102.61M | -69.77M |
| Financing Cash Flow | -30.36M | -74.93M | -178.06M | -47.20M | 26.72M | 879.71M |
Transcenta Holding Limited Technical Analysis
Neutral
2.25
Price Trends
0.90
Negative
1.04
Negative
1.65
Negative
Market Momentum
-0.08
Negative
46.62
Neutral
82.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6628, the sentiment is Neutral. The current price of 2.25 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 0.90, and above the 200-day MA of 1.65, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 46.62 is Neutral, neither overbought nor oversold. The STOCH value of 82.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6628.
Transcenta Holding Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% | |
53 Neutral | HK$5.69B | 19.83 | 17.36% | ― | 46.90% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$6.32B | -56.20 | -9.45% | ― | 68.12% | 81.84% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
43 Neutral | HK$327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% | |
41 Neutral | HK$7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
HK:6628
Transcenta Holding Limited
0.74
-2.32
-75.90%
HK:6998
Genor Biopharma Holdings Limited
1.62
-1.51
-48.24%
HK:9966
Alphamab Oncology
6.22
-5.47
-46.79%
HK:2157
Lepu Biopharma Co. Ltd. Class H
3.16
-3.23
-50.55%
HK:2171
CARsgen Therapeutics Holdings Ltd.
10.63
-6.92
-39.43%
HK:2616
CStone Pharmaceuticals
4.94
-1.28
-20.58%
Transcenta Holding Limited Corporate Events
Transcenta Seeks Shareholder Approval to Expand Equity Incentive Scheme
Oct 30, 2026
Transcenta Holding Limited has called an extraordinary general meeting for November 19, 2026, in Suzhou, China, to seek shareholder approval to refresh the mandate limit of its Share Incentive Scheme. The proposal would allow the company to issue ...
Transcenta Advances Licensing and Funding Drive to Ease Liquidity and Address Audit Disclaimer
Oct 27, 2026
Transcenta Holding Limited said it is pressing ahead with nine measures to ease liquidity pressures and strengthen its balance sheet, as it works to resolve a disclaimer of opinion raised in its 2025 annual report. The group is actively pursuing p...
Transcenta Receives First RMB95 Million Payment from Sale of CDMO Assets
Oct 20, 2026
Transcenta Holding Limited has received the first after-tax payment of RMB95 million from the sale of its CDMO assets to a wholly owned subsidiary of WuXi Biologics, under a total consideration of RMB190 million. The proceeds will be directed to g...
Transcenta Bolsters Claudin18.2 IP With New China Patent Backing Global Osemitamab Push
Oct 12, 2026
Transcenta Holding Limited has strengthened its intellectual property portfolio around its flagship Claudin18.2-targeting program, osemitamab (TST001), with a new China invention patent granted for anti-CLDN18.2 antibodies and their diagnostic use...
Transcenta Revises Share Incentive Grant for Director Prof. Genhong Cheng
Sep 30, 2026
Transcenta Holding Limited has revised the share-based remuneration for Director Prof. Genhong Cheng by cancelling a previous grant of 30,000 award shares that had not yet been transferred and replacing it with a new grant of the same number of sh...
Transcenta Shareholders Unanimously Approve Asset Purchase Deal
Sep 9, 2026
Transcenta Holding Limited, a Cayman Islands–registered biopharmaceutical company listed on the Hong Kong Stock Exchange, operates from Suzhou’s Biobay in China, where it develops and commercializes biologic therapies for healthcare ma...
Transcenta Adds Independent Director, Restores Compliance and Grants Share Award
Aug 28, 2026
Transcenta Holding Limited has appointed renowned microbiology and immunology expert Prof. Genhong Cheng as an independent non-executive director, effective August 28, 2026, bolstering the scientific depth and governance expertise of its board. Hi...
Transcenta Sets Out Board Composition and Committee Roles
Aug 28, 2026
Transcenta Holding Limited has disclosed the current composition of its board, led by Chief Executive Officer and Chairman Dr. Xueming Qian as the sole executive director, alongside two non-executive directors and three independent non-executive d...
Transcenta Narrows Loss as Revenue Surges on Out-Licensing and CDMO Growth
Aug 28, 2026
Transcenta reported a sharp rise in interim revenue to RMB23.6 million for the six months ended June 30, 2026, up from RMB2.7 million a year earlier, mainly driven by higher out-licensing income and expanded CDMO services. The shift indicates grow...
Transcenta Calls Extraordinary Meeting to Approve Asset Purchase Deal
Aug 24, 2026
Transcenta Holding Limited, registered by way of continuation in the Cayman Islands and listed on the Hong Kong Stock Exchange, maintains its principal operations hub in Hong Kong while convening key corporate meetings in Suzhou, China. The compan...
Transcenta Sets September EGM and Record Date for Asset Purchase Vote
Aug 21, 2026
Transcenta Holding Limited has scheduled an extraordinary general meeting for September 9, 2026, in Suzhou, China, where shareholders will be asked to consider and, if appropriate, approve an Asset Purchase Agreement and the related transaction. T...
Transcenta Sets August Board Meeting to Review Interim Results and Dividend
Aug 12, 2026
Transcenta Holding Limited has scheduled a board meeting for August 28, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026, and to consider the recommendation of an interim dividend. The meeting sig...
Transcenta to Sell Hangzhou CDMO Assets to WuXi Biologics for RMB190 Million
Aug 6, 2026
Transcenta Holding Limited has agreed to dispose of its CDMO assets in Hangzhou for a total consideration of RMB190 million, exiting ownership of a CDMO plant, related land use rights, buildings, equipment and associated operational assets. The bu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.